Zhang Baozhou, Liu Yifan, Zheng Jinwei, Chen Junping
Department of Anesthesiology, Ningbo No.2 Hospital, Ningbo, Zhejiang, China.
School of Medicine, Shaoxing University, Shaoxing, Zhejiang, China.
Front Psychiatry. 2025 Jun 25;16:1621830. doi: 10.3389/fpsyt.2025.1621830. eCollection 2025.
Patients suffering from depression frequently encounter extended periods of low moods and lack of enjoyment or enthusiasm for activities. It leads to suicidal thoughts and presents a potential hazard to their safety. Nowadays, there has been significant progress in researching the effectiveness and safety of esketamine in treating depression. Hence, this paper employs bibliometric analysis to investigate the evolution and future research trajectories of this domain.
We utilize Excel, VOSviewer, and CiteSpace software to generate bibliometric network visualizations to analyze, construct, and quantitatively evaluate pertinent literature, which facilitates a lucid and intuitive presentation of the trends and frontiers in this research domain.
Annual publications increased from 2015 to 2024, totaling 925 articles, with 286 studies published in 2024. The USA published the most papers (n=308), followed by China (n=260) and Canada (n=114). Three of the top journals were Journal of Affective Disorders (n=56,IF=4.90), Frontiers in Psychiatry (n=38,IF=5.44), and International Journal of Neuropsychopharmacology (n=21,IF=4.50). The most published authors were McIntyre, Roger S (n=52), followed by Hashimoto, Kenji (n=49), Rosenblat, Joshua D (n=41). The keywords that have been relevant to the topic for the last decade are "treatment-resistant depression", "efficacy", "antidepressant" and "suicidal ideation".
This bibliometric analysis showed a significant increase in research on the use of esketamine in the treatment of depression. The main focus of current research is still the assessment of long-term use safety. In addition, the huge difference in research resources between developed countries and low- and middle-income countries remains an unresolved issue.
抑郁症患者经常长时间情绪低落，对活动缺乏乐趣或热情。这会导致自杀念头，并对他们的安全构成潜在威胁。如今，艾氯胺酮治疗抑郁症的有效性和安全性研究取得了重大进展。因此，本文采用文献计量分析方法来研究该领域的发展演变及未来研究方向。
我们利用Excel、VOSviewer和CiteSpace软件生成文献计量网络可视化图，以分析、构建并定量评估相关文献，从而清晰直观地呈现该研究领域的趋势和前沿。
2015年至2024年年度发表量呈增长趋势，共计925篇文章，其中2024年发表了286项研究。美国发表的论文最多（n = 308），其次是中国（n = 260）和加拿大（n = 114）。排名前三的期刊是《情感障碍杂志》（n = 56，IF = 4.90）、《精神病学前沿》（n = 38，IF = 5.44）和《国际神经精神药理学杂志》（n = 21，IF = 4.50）。发表文章最多的作者是罗杰·S·麦金太尔（n = 52），其次是桥本健二（n = 49）、约书亚·D·罗森布拉特（n = 41）。过去十年与该主题相关的关键词是“难治性抑郁症”“疗效”“抗抑郁药”和“自杀意念”。
这项文献计量分析表明，艾氯胺酮治疗抑郁症的研究显著增加。当前研究的主要重点仍是长期使用安全性评估。此外，发达国家与低收入和中等收入国家在研究资源上的巨大差异仍是一个未解决的问题。
